NexgenRx Inc.
NEGXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $16,475 | $13,846 | $12,463 | $11,876 |
| % Growth | 19% | 11.1% | 4.9% | – |
| Cost of Goods Sold | $3,353 | $3,026 | $3,968 | $3,388 |
| Gross Profit | $13,122 | $10,820 | $8,495 | $8,488 |
| % Margin | 79.6% | 78.1% | 68.2% | 71.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $732 | $741 | $879 | $753 |
| SG&A Expenses | $1,383 | $1,274 | $8,415 | $6,327 |
| Sales & Mktg Exp. | $651 | $533 | $825 | $274 |
| Other Operating Expenses | $10,542 | $9,690 | $0 | $0 |
| Operating Expenses | $11,925 | $10,964 | $8,415 | $6,327 |
| Operating Income | $1,197 | -$144 | $79 | $2,161 |
| % Margin | 7.3% | -1% | 0.6% | 18.2% |
| Other Income/Exp. Net | -$171 | -$161 | -$253 | -$778 |
| Pre-Tax Income | $1,027 | -$305 | $133 | $2,025 |
| Tax Expense | $412 | $27 | $155 | -$2,023 |
| Net Income | $615 | -$332 | -$22 | $4,048 |
| % Margin | 3.7% | -2.4% | -0.2% | 34.1% |
| EPS | 0.006 | -0.005 | -0 | 0.058 |
| % Growth | 227.7% | -1,649% | -100.5% | – |
| EPS Diluted | 0.005 | -0.005 | -0 | 0.054 |
| Weighted Avg Shares Out | 70,930 | 70,531 | 70,336 | 70,336 |
| Weighted Avg Shares Out Dil | 76,530 | 70,531 | 70,336 | 74,836 |
| Supplemental Information | – | – | – | – |
| Interest Income | -$140 | -$123 | $206 | $55 |
| Interest Expense | $31 | $38 | $152 | $191 |
| Depreciation & Amortization | $1,266 | $1,308 | $1,393 | $1,345 |
| EBITDA | $2,324 | $1,031 | $1,678 | $4,334 |
| % Margin | 14.1% | 7.4% | 13.5% | 36.5% |